Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00502112
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸St.Vincent's Comprehensive Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT00495872
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2017-03-27
- Target Recruit Count
- 12
- Registration Number
- NCT00482911
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
- Conditions
- Interventions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 150
- Registration Number
- NCT00482261
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT00478777
- Locations
- 🇩🇪
Abt. Innere Medizin I , Hämatologie / Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪EPS - Early Phase Solutions GmbH, Jena, Germany
🇩🇪Direktor der Klinik f. Hämatologie, Universitätsklinikum Essen, Essen, Germany
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 53
- Registration Number
- NCT00478218
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT00477750
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 33
- Registration Number
- NCT00466921
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Leslie Andritsos
- Target Recruit Count
- 37
- Registration Number
- NCT00466895
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00460031
- Locations
- 🇺🇸
UHHS Westlake Medical Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.